{"hands_on_practices": [{"introduction": "A cornerstone assumption in dose-finding studies is that the probability of toxicity is non-decreasing with dose. However, random variability in small cohorts can lead to observed data that violates this assumptionâ€”for instance, observing more toxicity at a lower dose than a higher one. This exercise introduces the Pooled Adjacent Violators Algorithm (PAVA), an elegant non-parametric method to resolve such violations by producing a set of toxicity estimates that are consistent with the fundamental monotonicity principle, a crucial first step in many dose-finding analyses [@problem_id:5029471].", "problem": "A Phase I dose-escalation study in oncology aims to determine the Maximum Tolerated Dose (MTD), defined here as the highest dose whose estimated probability of dose-limiting toxicity (DLT) does not exceed a prespecified target toxicity rate $\\theta$. Assume the canonical monotonicity assumption for dose-toxicity in translational medicine: the DLT probability $p(d)$ is non-decreasing with dose $d$. Three ascending dose levels $d_{1}  d_{2}  d_{3}$ were each tested in cohorts of size $n_{i} = 6$, yielding observed DLT counts $x_{1} = 1$, $x_{2} = 0$, and $x_{3} = 2$.\n\nUse the following fundamental base:\n- At dose $d_{i}$, the DLT count $x_{i}$ follows a binomial model with probability $p(d_{i})$, that is $x_{i} \\sim \\mathrm{Binomial}(n_{i}, p(d_{i}))$.\n- The non-decreasing order restriction $p(d_{1}) \\leq p(d_{2}) \\leq p(d_{3})$ embodies the monotonic dose-toxicity assumption.\n- The nonparametric maximum likelihood estimator of the ordered probabilities under this monotonicity constraint is obtained by the pooled adjacent violators algorithm (PAVA), which replaces any adjacent violations of the order constraint by pooling and weighting by cohort sizes.\n\nTake the target toxicity rate to be $\\theta = 0.25$. Identify the MTD as the highest dose $d_{i}$ whose isotonic estimate $\\hat{p}(d_{i})$ is less than or equal to $\\theta$.\n\nTasks:\n1. Apply the pooled adjacent violators algorithm to the empirical DLT rates to produce monotone isotonic estimates $\\hat{p}(d_{1})$, $\\hat{p}(d_{2})$, and $\\hat{p}(d_{3})$.\n2. Using $\\theta = 0.25$, identify the MTD according to the rule stated above.\n\nRound all estimated probabilities to four significant figures. Express your final answer as a single row matrix containing, in order, $\\hat{p}(d_{1})$, $\\hat{p}(d_{2})$, $\\hat{p}(d_{3})$, and the MTD dose index (as an integer). No physical units are required for probabilities.", "solution": "The user wants me to solve a problem based on the following givens and tasks.\n\n### Step 1: Extract Givens\n- **Dose Levels**: Three ascending dose levels $d_1  d_2  d_3$.\n- **Cohort Sizes**: $n_1 = 6$, $n_2 = 6$, $n_3 = 6$.\n- **DLT Counts**: $x_1 = 1$, $x_2 = 0$, $x_3 = 2$.\n- **Statistical Model**: The number of dose-limiting toxicities (DLTs) at dose $d_i$, denoted by $x_i$, follows a binomial distribution: $x_i \\sim \\mathrm{Binomial}(n_i, p(d_i))$.\n- **Monotonicity Constraint**: The true DLT probabilities $p(d_i)$ are non-decreasing with dose: $p(d_1) \\leq p(d_2) \\leq p(d_3)$.\n- **Estimation Method**: The isotonic estimates of the probabilities, denoted $\\hat{p}(d_i)$, are to be found using the pooled adjacent violators algorithm (PAVA).\n- **Target Toxicity Rate**: $\\theta = 0.25$.\n- **MTD Definition**: The Maximum Tolerated Dose (MTD) is the highest dose level $d_i$ for which the estimated DLT probability $\\hat{p}(d_i)$ does not exceed $\\theta$, i.e., $\\hat{p}(d_i) \\leq \\theta$.\n- **Tasks**: 1. Compute the isotonic estimates $\\hat{p}(d_1)$, $\\hat{p}(d_2)$, and $\\hat{p}(d_3)$. 2. Identify the MTD dose index.\n- **Formatting**: Round probabilities to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is well-grounded in the statistical methods used for Phase I oncology trials. The binomial model for binary outcomes, the monotonicity assumption for dose-toxicity, and the use of isotonic regression (specifically PAVA) are standard and well-established practices in this field.\n- **Well-Posed**: The problem is clearly stated, providing all necessary data ($x_i, n_i$), parameters ($\\theta$), and a specific algorithm (PAVA) to compute the required quantities. The objective is unambiguous, leading to a unique solution.\n- **Objective**: The problem uses precise terminology from biostatistics and clinical trial design, devoid of any subjective or ambiguous language.\n\n### Step 3: Verdict and Action\nThe problem is valid as it is scientifically sound, well-posed, and objective. I will now proceed with the solution.\n\nThe problem requires us to first estimate the dose-limiting toxicity (DLT) probabilities for three dose levels, subject to a non-decreasing order constraint, and then to identify the Maximum Tolerated Dose (MTD) based on these estimates.\n\nThe initial, unconstrained maximum likelihood estimates of the DLT probabilities $p(d_i)$ are the empirical proportions of DLTs observed at each dose level. Let's denote these empirical rates as $p'_{i} = x_{i}/n_{i}$.\n\nFor dose level $d_1$:\n$$ p'_{1} = \\frac{x_{1}}{n_{1}} = \\frac{1}{6} $$\n\nFor dose level $d_2$:\n$$ p'_{2} = \\frac{x_{2}}{n_{2}} = \\frac{0}{6} = 0 $$\n\nFor dose level $d_3$:\n$$ p'_{3} = \\frac{x_{3}}{n_{3}} = \\frac{2}{6} = \\frac{1}{3} $$\n\nThe sequence of these empirical rates is $(p'_{1}, p'_{2}, p'_{3}) = (\\frac{1}{6}, 0, \\frac{1}{3})$. The monotonicity assumption requires that the estimated probabilities be non-decreasing, i.e., $\\hat{p}(d_1) \\leq \\hat{p}(d_2) \\leq \\hat{p}(d_3)$. We check if the empirical rates satisfy this condition.\n\nComparing $p'_{1}$ and $p'_{2}$:\n$$ p'_{1} = \\frac{1}{6} \\approx 0.1667 \\quad \\text{and} \\quad p'_{2} = 0 $$\nSince $p'_{1} > p'_{2}$, the monotonicity constraint is violated.\n\nThe Pooled Adjacent Violators Algorithm (PAVA) is used to correct this violation and produce the isotonic estimates $\\hat{p}(d_i)$. PAVA identifies adjacent pairs that violate the order and replaces them with their weighted average until no violations remain. The weights are the cohort sizes $n_i$.\n\nThe violation occurs between dose levels $d_1$ and $d_2$. We must pool the data from these two levels and compute a single new estimate for this block. The pooled estimate is the total number of DLTs in the block divided by the total number of patients in the block.\n\nPooled estimate for the block $\\{d_1, d_2\\}$:\n$$ \\hat{p}_{\\{1,2\\}} = \\frac{x_1 + x_2}{n_1 + n_2} = \\frac{1 + 0}{6 + 6} = \\frac{1}{12} $$\n\nThis pooled value replaces the individual estimates for $d_1$ and $d_2$. The working sequence of estimates becomes $(\\frac{1}{12}, \\frac{1}{12}, \\frac{1}{3})$.\n\nWe now check this new sequence for monotonicity:\n$$ \\frac{1}{12} \\leq \\frac{1}{12} \\leq \\frac{1}{3} $$\nNumerically, this is approximately $0.0833 \\leq 0.0833 \\leq 0.3333$, which is true. Since there are no more violations, the algorithm terminates.\n\nThe final isotonic estimates for the DLT probabilities are:\n$$ \\hat{p}(d_1) = \\frac{1}{12} $$\n$$ \\hat{p}(d_2) = \\frac{1}{12} $$\n$$ \\hat{p}(d_3) = \\frac{1}{3} $$\n\nThe problem requires rounding these probabilities to four significant figures.\n$$ \\hat{p}(d_1) = \\frac{1}{12} \\approx 0.083333... \\rightarrow 0.08333 $$\n$$ \\hat{p}(d_2) = \\frac{1}{12} \\approx 0.083333... \\rightarrow 0.08333 $$\n$$ \\hat{p}(d_3) = \\frac{1}{3} \\approx 0.333333... \\rightarrow 0.3333 $$\n\nNext, we identify the MTD. The MTD is defined as the highest dose $d_i$ for which the estimated DLT probability $\\hat{p}(d_i)$ is less than or equal to the target toxicity rate $\\theta = 0.25$.\n\nWe check this condition for each dose level:\n- For $d_1$: $\\hat{p}(d_1) = 0.08333$. Since $0.08333 \\leq 0.25$, dose $d_1$ is considered acceptable.\n- For $d_2$: $\\hat{p}(d_2) = 0.08333$. Since $0.08333 \\leq 0.25$, dose $d_2$ is also considered acceptable.\n- For $d_3$: $\\hat{p}(d_3) = 0.3333$. Since $0.3333 > 0.25$, dose $d_3$ is considered unacceptably toxic.\n\nThe set of acceptable doses is $\\{d_1, d_2\\}$. The MTD is the highest dose in this set, which is $d_2$. The problem asks for the MTD dose index, which is $2$.\n\nThe final answer requires a row matrix containing the three estimated probabilities and the MTD index.\nThe values are $\\hat{p}(d_1) = 0.08333$, $\\hat{p}(d_2) = 0.08333$, $\\hat{p}(d_3) = 0.3333$, and the MTD index is $2$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.08333  0.08333  0.3333  2\n\\end{pmatrix}\n}\n$$", "id": "5029471"}, {"introduction": "Beyond simple adjustments, modern dose-finding relies on robust statistical models to guide decisions. This practice moves into the world of model-based Bayesian methods, specifically the Bayesian Logistic Regression Model (BLRM), a workhorse in contemporary Phase I trials. Here, you will learn to use the full posterior distribution of the model's parameters to make a decision based on the Escalation with Overdose Control (EWOC) criterion, a rule that explicitly limits the risk of exposing future patients to unacceptably toxic doses [@problem_id:5029436].", "problem": "A Phase I dose-escalation study in translational medicine seeks to determine the Maximum Tolerated Dose (MTD) based on Dose-Limiting Toxicities (DLTs) using a Bayesian Logistic Regression Model (BLRM) with Escalation With Overdose Control (EWOC). The study evaluates doses $d \\in \\{5, 10, 20\\}$ mg in cohorts of $n_d$ patients, with observed counts $y_d$ of DLTs. The BLRM is defined by the logistic link\n$$\n\\text{logit}\\big(p(d)\\big) \\equiv \\ln\\left(\\frac{p(d)}{1 - p(d)}\\right) = \\alpha + \\beta \\ln\\left(\\frac{d}{d^{\\ast}}\\right),\n$$\nwhere $p(d)$ is the probability of DLT at dose $d$, $\\alpha$ and $\\beta$ are model parameters, and $d^{\\ast}$ is a fixed reference dose. The DLT counts are modeled as independent binomial outcomes\n$$\ny_d \\sim \\text{Binomial}\\big(n_d, p(d)\\big).\n$$\nYou are given the following data and modeling components:\n- Reference dose $d^{\\ast} = 10$ mg.\n- Observations: $y_{5} = 0$ of $n_{5} = 6$ at $5$ mg, $y_{10} = 1$ of $n_{10} = 6$ at $10$ mg, and $y_{20} = 2$ of $n_{20} = 6$ at $20$ mg.\n- Prior on $(\\alpha, \\beta)$: a weakly informative bivariate normal distribution with mean vector $\\boldsymbol{m}_{0} = (-2.0, 0.8)$ and covariance matrix\n$$\n\\boldsymbol{S}_{0} = \\begin{pmatrix}\n0.5  0 \\\\\n0  0.5\n\\end{pmatrix}.\n$$\n- After observing the data, a Laplace approximation (posterior mode and curvature) yields the approximate posterior for $(\\alpha, \\beta)$ as bivariate normal with mean vector $\\boldsymbol{m} = (-1.8, 1.0)$ and covariance matrix\n$$\n\\boldsymbol{S} = \\begin{pmatrix}\n0.16  -0.02 \\\\\n-0.02  0.05\n\\end{pmatrix}.\n$$\n\nFrom first principles, use Bayes' theorem and the logistic transformation to derive, for each $d \\in \\{5, 10, 20\\}$ mg, the posterior distribution of $p(d)$ implied by the normal approximation for $(\\alpha, \\beta)$. Then, using the Escalation With Overdose Control (EWOC) criterion with $\\omega = 0.25$ and target toxicity interval $[0.16, 0.33]$, do the following:\n1. For each dose $d$, compute the posterior probability that $p(d)$ is in the target interval $[0.16, 0.33]$.\n2. For each dose $d$, compute the posterior probability that $p(d)  0.33$.\n3. Identify the set of doses that satisfy EWOC, defined as those with $\\mathbb{P}\\big(p(d)  0.33 \\mid \\text{data}\\big)  \\omega$.\n4. Among doses that satisfy EWOC, select the recommended MTD as the dose that maximizes the posterior probability of $p(d)$ being in $[0.16, 0.33]$.\n\nReport the recommended MTD dose as a single number in milligrams. If any intermediate numerical probabilities are reported, round them to four significant figures. Express the final recommended dose in mg units (do not include units in the final boxed answer).", "solution": "The problem requires the determination of the Maximum Tolerated Dose (MTD) from a set of dose levels $d \\in \\{5, 10, 20\\}$ mg, based on a Bayesian Logistic Regression Model (BLRM) and the Escalation With Overdose Control (EWOC) criterion. The analysis utilizes an approximate bivariate normal posterior distribution for the model parameters $(\\alpha, \\beta)$.\n\nThe BLRM is defined by the equation:\n$$\n\\text{logit}\\big(p(d)\\big) = \\ln\\left(\\frac{p(d)}{1 - p(d)}\\right) = \\alpha + \\beta \\ln\\left(\\frac{d}{d^{\\ast}}\\right)\n$$\nwhere $p(d)$ is the probability of a Dose-Limiting Toxicity (DLT) at dose $d$, and $d^{\\ast}$ is a reference dose. Let us define the logit of the DLT probability at dose $d$ as $L(d) = \\text{logit}\\big(p(d)\\big)$. The model can be written as $L(d) = \\alpha + \\beta x_d$, where $x_d = \\ln(d/d^{\\ast})$.\n\nThe posterior distribution of the parameters $(\\alpha, \\beta)$ is given as an approximation to a bivariate normal distribution, $(\\alpha, \\beta)^T \\sim N(\\boldsymbol{m}, \\boldsymbol{S})$, with mean vector and covariance matrix:\n$$\n\\boldsymbol{m} = \\begin{pmatrix} m_\\alpha \\\\ m_\\beta \\end{pmatrix} = \\begin{pmatrix} -1.8 \\\\ 1.0 \\end{pmatrix}, \\quad \\boldsymbol{S} = \\begin{pmatrix} S_{\\alpha\\alpha}  S_{\\alpha\\beta} \\\\ S_{\\beta\\alpha}  S_{\\beta\\beta} \\end{pmatrix} = \\begin{pmatrix} 0.16  -0.02 \\\\ -0.02  0.05 \\end{pmatrix}\n$$\nSince $L(d)$ is a linear transformation of the normally distributed vector $(\\alpha, \\beta)^T$, its posterior distribution is also normal. Specifically, $L(d) = \\boldsymbol{c}_d^T (\\alpha, \\beta)^T$ where $\\boldsymbol{c}_d^T = (1, x_d)$. The posterior distribution of $L(d)$ is $L(d) \\sim N(\\mu_{L(d)}, \\sigma_{L(d)}^2)$, with mean and variance given by:\n$$\n\\mu_{L(d)} = \\boldsymbol{c}_d^T \\boldsymbol{m} = m_\\alpha + m_\\beta x_d\n$$\n$$\n\\sigma_{L(d)}^2 = \\boldsymbol{c}_d^T \\boldsymbol{S} \\boldsymbol{c}_d = S_{\\alpha\\alpha} + 2S_{\\alpha\\beta}x_d + S_{\\beta\\beta}x_d^2\n$$\n\nWe first calculate the parameters of the posterior distribution for $L(d)$ for each dose level, using the given reference dose $d^{\\ast} = 10$ mg.\n\nFor $d = 5$ mg:\nThe term $x_5 = \\ln(5/10) = \\ln(0.5) = -\\ln(2)$.\n$\\mu_{L(5)} = -1.8 + 1.0 \\times (-\\ln(2)) \\approx -1.8 - 0.6931 = -2.4931$.\n$\\sigma_{L(5)}^2 = 0.16 + 2(-0.02)(-\\ln(2)) + 0.05(-\\ln(2))^2 \\approx 0.16 + 0.04(0.6931) + 0.05(0.4805) \\approx 0.16 + 0.02772 + 0.02402 = 0.2117$.\nThe standard deviation is $\\sigma_{L(5)} = \\sqrt{0.2117} \\approx 0.4601$.\n\nFor $d = 10$ mg:\nThe term $x_{10} = \\ln(10/10) = \\ln(1) = 0$.\n$\\mu_{L(10)} = -1.8 + 1.0 \\times 0 = -1.8$.\n$\\sigma_{L(10)}^2 = 0.16 + 2(-0.02)(0) + 0.05(0)^2 = 0.16$.\nThe standard deviation is $\\sigma_{L(10)} = \\sqrt{0.16} = 0.4$.\n\nFor $d = 20$ mg:\nThe term $x_{20} = \\ln(20/10) = \\ln(2)$.\n$\\mu_{L(20)} = -1.8 + 1.0 \\times \\ln(2) \\approx -1.8 + 0.6931 = -1.1069$.\n$\\sigma_{L(20)}^2 = 0.16 + 2(-0.02)(\\ln(2)) + 0.05(\\ln(2))^2 \\approx 0.16 - 0.04(0.6931) + 0.05(0.4805) \\approx 0.16 - 0.02772 + 0.02402 = 0.1563$.\nThe standard deviation is $\\sigma_{L(20)} = \\sqrt{0.1563} \\approx 0.3953$.\n\nNext, we must transform the probability-space intervals of interest into logit-space. The target toxicity interval is $[0.16, 0.33]$.\nThe lower bound in logit-space is $L_{lower} = \\text{logit}(0.16) = \\ln\\left(\\frac{0.16}{1 - 0.16}\\right) = \\ln\\left(\\frac{0.16}{0.84}\\right) \\approx -1.6582$.\nThe upper bound is $L_{upper} = \\text{logit}(0.33) = \\ln\\left(\\frac{0.33}{1 - 0.33}\\right) = \\ln\\left(\\frac{0.33}{0.67}\\right) \\approx -0.7082$.\nThe overdose threshold is $p(d) > 0.33$, which corresponds to $L(d) > -0.7082$.\n\nLet $\\Phi(z)$ be the cumulative distribution function (CDF) of the standard normal distribution. We now compute the required probabilities for each dose.\n\nFor $d = 5$ mg, with $L(5) \\sim N(-2.4931, 0.4601^2)$:\n1. Probability in target interval:\n$\\mathbb{P}\\big(p(5) \\in [0.16, 0.33]\\big) = \\mathbb{P}\\big(-1.6582 \\le L(5) \\le -0.7082\\big)$\n$= \\Phi\\left(\\frac{-0.7082 - (-2.4931)}{0.4601}\\right) - \\Phi\\left(\\frac{-1.6582 - (-2.4931)}{0.4601}\\right)$\n$= \\Phi(3.879) - \\Phi(1.815) \\approx 0.999948 - 0.96523 = 0.03472$. Rounded to four significant figures, this is $0.03472$.\n2. Overdose probability:\n$\\mathbb{P}\\big(p(5) > 0.33\\big) = \\mathbb{P}\\big(L(5) > -0.7082\\big) = 1 - \\Phi\\left(\\frac{-0.7082 - (-2.4931)}{0.4601}\\right)$\n$= 1 - \\Phi(3.879) \\approx 1 - 0.999948 = 0.000052$. Rounded to four significant figures, this is $0.00005200$.\n\nFor $d = 10$ mg, with $L(10) \\sim N(-1.8, 0.4^2)$:\n1. Probability in target interval:\n$\\mathbb{P}\\big(p(10) \\in [0.16, 0.33]\\big) = \\mathbb{P}\\big(-1.6582 \\le L(10) \\le -0.7082\\big)$\n$= \\Phi\\left(\\frac{-0.7082 - (-1.8)}{0.4}\\right) - \\Phi\\left(\\frac{-1.6582 - (-1.8)}{0.4}\\right)$\n$= \\Phi(2.7295) - \\Phi(0.3545) \\approx 0.99682 - 0.63854 = 0.35828$. Rounded to four significant figures, this is $0.3583$.\n2. Overdose probability:\n$\\mathbb{P}\\big(p(10) > 0.33\\big) = \\mathbb{P}\\big(L(10) > -0.7082\\big) = 1 - \\Phi\\left(\\frac-0.7082 - (-1.8)}{0.4}\\right)$\n$= 1 - \\Phi(2.7295) \\approx 1 - 0.99682 = 0.00318$. Rounded to four significant figures, this is $0.003180$.\n\nFor $d = 20$ mg, with $L(20) \\sim N(-1.1069, 0.3953^2)$:\n1. Probability in target interval:\n$\\mathbb{P}\\big(p(20) \\in [0.16, 0.33]\\big) = \\mathbb{P}\\big(-1.6582 \\le L(20) \\le -0.7082\\big)$\n$= \\Phi\\left(\\frac{-0.7082 - (-1.1069)}{0.3953}\\right) - \\Phi\\left(\\frac{-1.6582 - (-1.1069)}{0.3953}\\right)$\n$= \\Phi(1.0086) - \\Phi(-1.3949) = \\Phi(1.0086) - (1 - \\Phi(1.3949))$\n$\\approx 0.84347 - (1 - 0.91845) = 0.84347 - 0.08155 = 0.76192$. Rounded to four significant figures, this is $0.7619$.\n2. Overdose probability:\n$\\mathbb{P}\\big(p(20) > 0.33\\big) = \\mathbb{P}\\big(L(20) > -0.7082\\big) = 1 - \\Phi\\left(\\frac{-0.7082 - (-1.1069)}{0.3953}\\right)$\n$= 1 - \\Phi(1.0086) \\approx 1 - 0.84347 = 0.15653$. Rounded to four significant figures, this is $0.1565$.\n\nNow we apply the decision criteria.\nFirst, identify the set of admissible doses using the EWOC criterion: $\\mathbb{P}\\big(p(d) > 0.33 \\mid \\text{data}\\big)  \\omega$, with $\\omega = 0.25$.\n- For $d=5$ mg: $\\mathbb{P}\\big(p(5) > 0.33\\big) \\approx 0.00005200  0.25$. The dose is admissible.\n- For $d=10$ mg: $\\mathbb{P}\\big(p(10) > 0.33\\big) \\approx 0.003180  0.25$. The dose is admissible.\n- For $d=20$ mg: $\\mathbb{P}\\big(p(20) > 0.33\\big) \\approx 0.1565  0.25$. The dose is admissible.\nAll three doses, $\\{5, 10, 20\\}$ mg, are in the set of admissible doses.\n\nSecond, among the admissible doses, select the MTD as the dose that maximizes the posterior probability of $p(d)$ being in the target interval $[0.16, 0.33]$.\n- $\\mathbb{P}\\big(p(5) \\in [0.16, 0.33]\\big) \\approx 0.03472$\n- $\\mathbb{P}\\big(p(10) \\in [0.16, 0.33]\\big) \\approx 0.3583$\n- $\\mathbb{P}\\big(p(20) \\in [0.16, 0.33]\\big) \\approx 0.7619$\n\nComparing these probabilities, the maximum is $0.7619$, which corresponds to the dose $d = 20$ mg.\n\nTherefore, the recommended MTD is $20$ mg.", "answer": "$$\\boxed{20}$$", "id": "5029436"}, {"introduction": "The frontier of translational medicine lies in personalization, and this principle extends to determining safe and effective doses. Recognizing that a single Maximum Tolerated Dose (MTD) may not be suitable for all, this advanced practice explores how to tailor dosing using patient-specific characteristics. You will work with a covariate-adjusted Bayesian model to compute individualized DLT probabilities for a new patient based on their age and renal function, moving from a \"one-size-fits-all\" approach to a truly personalized dosing strategy [@problem_id:5029481].", "problem": "A single-agent first-in-human oncology Phase I study uses a covariate-adjusted Bayesian dose-finding model to individualize dosing to a target dose-limiting toxicity (DLT) probability. The binary DLT outcome is modeled with a probit link. For a patient receiving dose $d$ (in mg) with covariates age $a$ (in years) and renal function measured by estimated glomerular filtration rate $r$ (in mL/min per $1.73$ m$^2$), the model specifies the DLT probability\n$\n\\pi(d,a,r) \\;=\\; \\Phi\\!\\big(\\eta(d,a,r)\\big),\n$\nwhere $\\Phi(\\cdot)$ is the standard normal cumulative distribution function and\n$\n\\eta(d,a,r) \\;=\\; \\beta_{0} \\;+\\; \\beta_{1}\\,\\ln\\!\\big(d/40\\big) \\;+\\; \\gamma_{a}\\,\\frac{a-60}{10} \\;+\\; \\gamma_{k}\\,\\frac{60-r}{15}.\n$\nAfter analyzing data from previously treated patients, the joint posterior distribution of the parameter vector $\\theta = (\\beta_{0},\\beta_{1},\\gamma_{a},\\gamma_{k})^{\\top}$ is approximated by a multivariate normal distribution with mean vector\n$\n\\mu \\;=\\; \\begin{pmatrix} -0.85 \\\\ 0.60 \\\\ 0.20 \\\\ 0.40 \\end{pmatrix}\n$\nand diagonal covariance matrix\n$\n\\Sigma \\;=\\; \\mathrm{diag}\\!\\big(0.09,\\;0.04,\\;0.0225,\\;0.0225\\big).\n$\nA new patient presents with age $a = 68$ and estimated glomerular filtration rate $r = 45$. The candidate dose set is $\\mathcal{D} = \\{\\,20,\\,30,\\,40,\\,60,\\,80\\,\\}$ (mg). The design targets a DLT probability of $p^{\\ast} = 0.25$. For this new patient, compute the patient-specific posterior mean DLT probability $\\mathbb{E}\\big[\\pi(d,a,r)\\,\\big|\\,\\mathrm{data}\\big]$ for each $d \\in \\mathcal{D}$ by integrating over the posterior of $\\theta$, and then recommend the individualized dose in $\\mathcal{D}$ whose posterior mean DLT probability is closest (in absolute difference) to $p^{\\ast}$. Use the natural logarithm $\\ln(\\cdot)$. Report only the recommended dose in mg. Because the recommendation is chosen from a finite set, no rounding is required.", "solution": "The problem requires the determination of the optimal dose for a new patient from a discrete set of candidate doses $\\mathcal{D} = \\{20, 30, 40, 60, 80\\}$ mg. The criterion for optimality is to select the dose $d$ for which the posterior mean dose-limiting toxicity (DLT) probability, $\\mathbb{E}[\\pi(d,a,r) | \\mathrm{data}]$, is closest to the target DLT probability $p^{\\ast} = 0.25$.\n\nThe DLT probability for a patient with age $a$ and estimated glomerular filtration rate $r$ receiving dose $d$ is given by the probit model:\n$$\n\\pi(d,a,r) = \\Phi(\\eta(d,a,r))\n$$\nwhere $\\Phi(\\cdot)$ is the standard normal cumulative distribution function (CDF), and the linear predictor $\\eta(d,a,r)$ is\n$$\n\\eta(d,a,r) = \\beta_{0} + \\beta_{1}\\,\\ln(d/40) + \\gamma_{a}\\,\\frac{a-60}{10} + \\gamma_{k}\\,\\frac{60-r}{15}\n$$\nThe parameter vector $\\theta = (\\beta_{0}, \\beta_{1}, \\gamma_{a}, \\gamma_{k})^{\\top}$ is treated as a random variable. Its posterior distribution, given the data from previously treated patients, is approximated by a multivariate normal distribution $\\theta \\sim \\mathcal{N}(\\mu, \\Sigma)$, with mean vector $\\mu$ and covariance matrix $\\Sigma$ given as:\n$$\n\\mu = \\begin{pmatrix} -0.85 \\\\ 0.60 \\\\ 0.20 \\\\ 0.40 \\end{pmatrix}, \\quad \\Sigma = \\mathrm{diag}(0.09, 0.04, 0.0225, 0.0225)\n$$\nFor a new patient, the covariates $a$ and $r$, and the dose $d$ are fixed. The linear predictor $\\eta(d,a,r)$ can be written as a linear transformation of the parameter vector $\\theta$:\n$$\n\\eta(d,a,r) = X(d,a,r)^{\\top}\\theta\n$$\nwhere $X(d,a,r)$ is a vector of covariates:\n$$\nX(d,a,r) = \\begin{pmatrix} 1 \\\\ \\ln(d/40) \\\\ \\frac{a-60}{10} \\\\ \\frac{60-r}{15} \\end{pmatrix}\n$$\nSince $\\theta$ is normally distributed, the linear predictor $\\eta(d,a,r)$ is also normally distributed. Its posterior distribution is $\\eta(d,a,r) \\sim \\mathcal{N}(\\mu_{\\eta}, \\sigma_{\\eta}^2)$, with mean and variance given by:\n$$\n\\mu_{\\eta}(d,a,r) = \\mathbb{E}[X(d,a,r)^{\\top}\\theta] = X(d,a,r)^{\\top}\\mu\n$$\n$$\n\\sigma_{\\eta}^2(d,a,r) = \\mathrm{Var}(X(d,a,r)^{\\top}\\theta) = X(d,a,r)^{\\top}\\Sigma X(d,a,r)\n$$\nThe task is to compute the posterior mean DLT probability, which is the expectation of $\\Phi(\\eta(d,a,r))$ over the posterior distribution of $\\eta(d,a,r)$. Let $Z \\sim \\mathcal{N}(\\mu_Z, \\sigma_Z^2)$. We need to calculate $\\mathbb{E}[\\Phi(Z)]$. This expectation can be found by introducing an independent standard normal variable $Y \\sim \\mathcal{N}(0,1)$:\n$$\n\\mathbb{E}[\\Phi(Z)] = \\mathbb{E}[P(Y \\le Z | Z)] = P(Y \\le Z) = P(Y - Z \\le 0)\n$$\nThe variable $W = Y - Z$ is a linear combination of independent normal variables, so it is also normal. Its mean is $\\mathbb{E}[W] = \\mathbb{E}[Y] - \\mathbb{E}[Z] = 0 - \\mu_Z = -\\mu_Z$. Its variance is $\\mathrm{Var}(W) = \\mathrm{Var}(Y) + \\mathrm{Var}(-Z) = \\mathrm{Var}(Y) + \\mathrm{Var}(Z) = 1 + \\sigma_Z^2$. Thus, $W \\sim \\mathcal{N}(-\\mu_Z, 1 + \\sigma_Z^2)$. The desired probability is:\n$$\nP(W \\le 0) = P\\left(\\frac{W - (-\\mu_Z)}{\\sqrt{1+\\sigma_Z^2}} \\le \\frac{0 - (-\\mu_Z)}{\\sqrt{1+\\sigma_Z^2}}\\right) = \\Phi\\left(\\frac{\\mu_Z}{\\sqrt{1+\\sigma_Z^2}}\\right)\n$$\nApplying this result, the posterior mean DLT probability is:\n$$\n\\mathbb{E}[\\pi(d,a,r) | \\mathrm{data}] = \\Phi\\left(\\frac{\\mu_{\\eta}(d,a,r)}{\\sqrt{1+\\sigma_{\\eta}^2(d,a,r)}}\\right)\n$$\nFor the new patient, $a = 68$ and $r = 45$. The patient-specific covariate terms are:\n$$\n\\frac{a-60}{10} = \\frac{68-60}{10} = 0.8 \\quad \\text{and} \\quad \\frac{60-r}{15} = \\frac{60-45}{15} = 1\n$$\nWe compute $\\mu_{\\eta}$ and $\\sigma_{\\eta}^2$ for this patient as a function of dose $d$:\n$$\n\\mu_{\\eta}(d) = \\begin{pmatrix} 1  \\ln(d/40)  0.8  1 \\end{pmatrix} \\begin{pmatrix} -0.85 \\\\ 0.60 \\\\ 0.20 \\\\ 0.40 \\end{pmatrix} = -0.85 + 0.60\\ln(d/40) + 0.20(0.8) + 0.40(1)\n$$\n$$\n\\mu_{\\eta}(d) = -0.85 + 0.16 + 0.40 + 0.60\\ln(d/40) = -0.29 + 0.60\\ln(d/40)\n$$\nSince $\\Sigma$ is diagonal, the variance calculation simplifies:\n$$\n\\sigma_{\\eta}^2(d) = (1)^2\\sigma_{\\beta_0}^2 + (\\ln(d/40))^2\\sigma_{\\beta_1}^2 + (0.8)^2\\sigma_{\\gamma_a}^2 + (1)^2\\sigma_{\\gamma_k}^2\n$$\n$$\n\\sigma_{\\eta}^2(d) = 0.09 + 0.04(\\ln(d/40))^2 + (0.64)(0.0225) + (1)(0.0225)\n$$\n$$\n\\sigma_{\\eta}^2(d) = 0.09 + 0.0144 + 0.0225 + 0.04(\\ln(d/40))^2 = 0.1269 + 0.04(\\ln(d/40))^2\n$$\nNow, we evaluate the posterior mean DLT probability for each dose $d \\in \\mathcal{D}$ and find its absolute difference from $p^{\\ast} = 0.25$.\n\nFor $d=20$:\n$\\ln(20/40) = -\\ln(2) \\approx -0.6931$\n$\\mu_{\\eta}(20) = -0.29 + 0.60(-\\ln(2)) \\approx -0.7059$\n$\\sigma_{\\eta}^2(20) = 0.1269 + 0.04(-\\ln(2))^2 \\approx 0.1461$\n$\\mathbb{E}[\\pi(20)] = \\Phi\\left(\\frac{-0.7059}{\\sqrt{1+0.1461}}\\right) \\approx \\Phi\\left(\\frac{-0.7059}{1.0706}\\right) \\approx \\Phi(-0.6594) \\approx 0.2548$\n$|\\mathbb{E}[\\pi(20)] - 0.25| = |0.2548 - 0.25| = 0.0048$\n\nFor $d=30$:\n$\\ln(30/40) = \\ln(0.75) \\approx -0.2877$\n$\\mu_{\\eta}(30) = -0.29 + 0.60(\\ln(0.75)) \\approx -0.4626$\n$\\sigma_{\\eta}^2(30) = 0.1269 + 0.04(\\ln(0.75))^2 \\approx 0.1302$\n$\\mathbb{E}[\\pi(30)] = \\Phi\\left(\\frac{-0.4626}{\\sqrt{1+0.1302}}\\right) \\approx \\Phi\\left(\\frac{-0.4626}{1.0631}\\right) \\approx \\Phi(-0.4351) \\approx 0.3318$\n$|\\mathbb{E}[\\pi(30)] - 0.25| = |0.3318 - 0.25| = 0.0818$\n\nFor $d=40$:\n$\\ln(40/40) = \\ln(1) = 0$\n$\\mu_{\\eta}(40) = -0.29$\n$\\sigma_{\\eta}^2(40) = 0.1269$\n$\\mathbb{E}[\\pi(40)] = \\Phi\\left(\\frac{-0.29}{\\sqrt{1+0.1269}}\\right) \\approx \\Phi\\left(\\frac{-0.29}{1.0616}\\right) \\approx \\Phi(-0.2732) \\approx 0.3924$\n$|\\mathbb{E}[\\pi(40)] - 0.25| = |0.3924 - 0.25| = 0.1424$\n\nFor $d=60$:\n$\\ln(60/40) = \\ln(1.5) \\approx 0.4055$\n$\\mu_{\\eta}(60) = -0.29 + 0.60(\\ln(1.5)) \\approx -0.0467$\n$\\sigma_{\\eta}^2(60) = 0.1269 + 0.04(\\ln(1.5))^2 \\approx 0.1335$\n$\\mathbb{E}[\\pi(60)] = \\Phi\\left(\\frac{-0.0467}{\\sqrt{1+0.1335}}\\right) \\approx \\Phi\\left(\\frac{-0.0467}{1.0646}\\right) \\approx \\Phi(-0.0439) \\approx 0.4825$\n$|\\mathbb{E}[\\pi(60)] - 0.25| = |0.4825 - 0.25| = 0.2325$\n\nFor $d=80$:\n$\\ln(80/40) = \\ln(2) \\approx 0.6931$\n$\\mu_{\\eta}(80) = -0.29 + 0.60(\\ln(2)) \\approx 0.1259$\n$\\sigma_{\\eta}^2(80) = 0.1269 + 0.04(\\ln(2))^2 \\approx 0.1461$\n$\\mathbb{E}[\\pi(80)] = \\Phi\\left(\\frac{0.1259}{\\sqrt{1+0.1461}}\\right) \\approx \\Phi\\left(\\frac{0.1259}{1.0706}\\right) \\approx \\Phi(0.1176) \\approx 0.5468$\n$|\\mathbb{E}[\\pi(80)] - 0.25| = |0.5468 - 0.25| = 0.2968$\n\nComparing the absolute differences:\n- Dose $20$ mg: $0.0048$\n- Dose $30$ mg: $0.0818$\n- Dose $40$ mg: $0.1424$\n- Dose $60$ mg: $0.2325$\n- Dose $80$ mg: $0.2968$\n\nThe minimum absolute difference is $0.0048$, which corresponds to the dose of $20$ mg. Therefore, this is the recommended individualized dose for the new patient.", "answer": "$$\\boxed{20}$$", "id": "5029481"}]}